GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

LXRX · Mar 31, 2026

LEXICON PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001062822-26-000101General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

235.45% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generation88thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-69.80% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

1572.11% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure38thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

1.31% · OPTIONAL · VALID

Gross margin75thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.gross_margin

99.49% · CORE · VALID

Operating margin88thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.operating_margin

-4.72% · CORE · VALID

R&D intensity13thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

60.45% · OPTIONAL · VALID

SBC intensity13thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

14.59% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History10 statesHistory building
Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20240/7 normalizedLevel 3Mar 31, 20250/8 normalizedLevel 3Jun 30, 20250/7 normalizedLevel 3Sep 30, 20250/8 normalizedLevel 3Dec 31, 20250/9 normalizedLevel 3Mar 31, 20266/8 normalizedLevel 3Jun 30, 20266/8 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
108.43%
Current
235.45%
Delta
127.01%
Cash Generation Increased
Previous
-136.24%
Current
-69.80%
Delta
66.44%
Growth Increased
Previous
729.91%
Current
1572.11%
Delta
842.20%
Inventory Pressure Increased
Previous
0.56%
Current
1.31%
Delta
0.74%
Margin Increased
Previous
99.45%
Current
99.49%
Delta
0.04%
Profitability Increased
Previous
-98.21%
Current
-4.72%
Delta
93.49%
R And D Intensity Decreased
Previous
122.73%
Current
60.45%
Delta
-62.28%
Sbc Intensity Decreased
Previous
25.13%
Current
14.59%
Delta
-10.55%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · LXRX Fundamental State →Has State · LEXICON PHARMACEUTICALS, INC. →Transitioned To · LXRX Fundamental State →Transitioned To · LXRX BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · LXRX CASH_GENERATION_INCREASED →Transitioned To · LXRX GROWTH_INCREASED →Transitioned To · LXRX INVENTORY_PRESSURE_INCREASED →Transitioned To · LXRX MARGIN_INCREASED →Transitioned To · LXRX PROFITABILITY_INCREASED →Transitioned To · LXRX R_AND_D_INTENSITY_DECREASED →Transitioned To · LXRX SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.